- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease -PRINCETON, N.J., Feb. 08,…
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and…
SUNNYVALE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on…
CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new…
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight…
WAYNE, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth…
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…
Toronto, Ontario--(Newsfile Corp. - February 8, 2024) - Safe Supply Streaming Co. Ltd. ("Safe Supply" or "the Company") (CSE: SPLY)…
The Best in KLAS report recognizes organizations who support healthcare providers that deliver optimized patient care, and the awards are…
Fourth quarter GAAP revenues of $214.9 million; fourth quarter Adjusted revenues of $214.9 million, up 6% from the prior year…